Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen Adds to RNAi Product line with Sequitur Acquisition

NEW YORK, Nov. 4 (GenomeWeb News) - Invitrogen said today that it has acquired privately held RNAi technology firm Sequitur of Natick, Mass.

Financial terms of the acquisition were not disclosed.

Claude Benchimol, Invitrogen's senior vice president of R&D, said that the acquisition will add to Invitrogen's "growing RNAi platform." Benchimol said that Sequitur's Stealth RNAi technology, which uses proprietary chemically modified synthetic RNAi molecules, performs "better than conventional short-interfering RNA" and can be combined with Invitrogen's Lipofectamine transfection reagents.

Invitrogen's RNAi product line, marketed under the Block-it trade name, includes transfection agents, vectors, oligonucleotides, and other products.

"With its patent position, we believe Sequitur Inc.'s Stealth technology will prevail as the standard method for how researchers perform RNAi," said Invitrogen CEO Gregory Lucier.

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.